Introduction: Lactose intolerance is highly prevalent in the Mediterranean area. A substantial proportion of patients remain symptomatic in spite of fair lactose-free diet. Aims: Assess in a series of IBS consecutive patients: 1.) the prevalence of lactose intolerance, 2.) the frequency of association of lactose intolerance with SIBO, 3.) the possibility of SIBO as a cause of symptom persistence in patients with lactose intolerance on lactose-free diet, and 4.) the ability of LHBT to diagnose SIBO. Methods: Lactose malabsorption was assessed by means of LHBT and SIBO by means of GHBT and LHBT, using Breath Tracker digital microlyzer on 500 IBS patients and 50 controls. SIBO was treated, with rifaximin 1,200 mg a day for 2 weeks, randomly, on 1 to 1 basis. Results: Prevalence of lactose intolerance resulted to be 59% in IBS patients and 6% in controls, with a statistically signifi cant diff erence (p<.001). SIBO was present in 72% of patients with lactose intolerance in IBS group, ad in none of the subjects with lactose malabsorption (3) in control group. Aft er 6 months, 105 out of 106 patients aff ected by LI + SIBO treated with rifaximin + lactose free diet, and 34 out of 107 patients aff ected by LI + SIBO treated only with a lactose free diet resulted completely asymptomatic. Concordance between LHBT and GHBT for SIBO diagnosis was 98%. Conclusion: Lactose intolerance is a common condition in patients with IBS in northwest Italy (59%), very frequently associated with SIBO (72%). Th is association turned out to be a major cause of symptom persistence in patients on lactose-free diet until successful eradication of SIBO was achieved. LHBT is a simple test able to diagnose simultaneously lactose malabsorption and SIBO.
Introduction: Celiac disease (CeD) is now known to be a systemic disease with manifestations not limited to small intestine. Th e data on association between CeD and infertility is contradictory. Neither gynecological societies nor gastroenterological societies have provided any recommendation for the screening of female patients with infertility for CeD. We therefore conducted a meta-analysis of available studies to fi nd out if women with infertility are at higher risk of CeD. Methods: We searched Medline, Pubmed, and directory of open access journals using the MeSH keyowrds "celiac disease, " "gluten, " and "infertility. " Diagnosis of CeD was based on positive serology and duodenal biopsy showing villous atrophy. Data was extracted about CeD patients in each of 3 groups: women with infertility (including unexplained infertility), unexplained infertile, and controls. Pooled odds ratio (OR) and prevalence, with 95% confi dence intervals (CI), were calculated. Results: Of available 105 relevant studies, 6 studies which met required inclusion and exclusion criteria were included for calculation of pooled OR. Four additional studies, where data on controls was not available, were also considered for calculation of pooled prevalence of CeD in women with infertility. Women with infertility had 4.6 times higher odds of having CeD in comparison to that in control population (OR 4.6; 95% CI 2.2, 9.7; p<.001) . Similarly, women with unexplained infertility also had 6 times higher odds of having CeD in comparison to control population (OR 6; 95% CI 2.4, 14.6). Of total 1,084 women with infertility, 26 had CeD indicating a pooled prevalence of CeD to be 2.4% (95% CI-1.6-3.5). Of 623 women with unexplained infertility, 20 had CeD. Th e pooled prevalence of CeD in women with unexplained infertility was 3.2 (95% CI 2, 4.9). Th ere was no evidence of publication bias. Conclusion: Women with infertility are at higher risk of CeD, and they should be screened for CeD.
[349] [350A] Figure 1 . Pooled odds ratio for celiac disease in women with infertility compared with control population.
